


Azvudine

Cat. No.:	HY-19314
CAS No.:	1011529-10-4
Molecular Formula:	C ₉ H ₁₁ FN ₆ O ₄
Molecular Weight:	286.22
Target:	Reverse Transcriptase; HIV; HBV; HCV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Azvudine (RO-0622) is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and HCV. Azvudine exerts highly potent inhibition on HIV-1 (EC ₅₀ s ranging from 0.03 to 6.92 nM) and HIV-2 (EC ₅₀ s ranging from 0.018 to 0.025 nM). Azvudine inhibits NRTI-resistant viral strains ^[1] .	
IC₅₀ & Target	HIV-1 0.03-6.92 nM (EC ₅₀)	HIV-2 0.018-0.02 nM (EC ₅₀)
In Vitro	Azvudine (RO-0622) displays strong inhibition on wild-type HIV-1 _{IIIB} and HIV-1 _{RF} with an EC ₅₀ ranging from 30 to 110 pM. The EC ₅₀ values of Azvudine against HIV-1 _{KM018} , HIV-1 _{TC-1} and HIV-1 _{WAN T69N} are 6.92, 0.34 and 0.45 nM, respectively. Azvudine is sensitive to NRTIs-resistant strain HIV-1 _{74V} , PIs-resistant strains HIV-1 _{L10R/M46I/L63P/V82T/I84V} and HIV-1 _{RF V82F/184V} , and FIs-resistant strain pNL4-3 _{gp41 (36G) V38A/N42T} . The EC ₅₀ values of Azvudine against these resistant strains are 0.11, 0.14, 0.37 and 0.36 nM respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

[1]. Wang RR, et al. Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro. PLoS One. 2014 Aug 21;9(8):e105617.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA